One-Time Use of Galcanezumab or Fremanezumab for Migraine Prevention

Background There are no reports on the effectiveness of one-time use of the calcitonin gene-related peptide-related monoclonal antibodies (CGRP-mABs) evaluated at one and three months for migraine prevention. Here, we present the real-world data of one-time administration of CGRP-mABs, galcanezumab...

Descripción completa

Detalles Bibliográficos
Autores principales: Katsuki, Masahito, Kashiwagi, Kenta, Kawamura, Shin, Tachikawa, Senju, Koh, Akihito
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Internal Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9951121/
https://www.ncbi.nlm.nih.gov/pubmed/36843788
http://dx.doi.org/10.7759/cureus.34180

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9951121/
https://www.ncbi.nlm.nih.gov/pubmed/36843788
http://dx.doi.org/10.7759/cureus.34180

Ejemplares similares